AVITA Medical to Host Investor Webinar Briefing
14 Août 2023 - 2:00PM
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative
medicine company leading the development and commercialization of
first-in-class devices and autologous cellular therapies for skin
restoration, invites shareholders and prospective investors to
attend its investor webinar briefing and presentation by Jim
Corbett, CEO, and David O’Toole, CFO, on August 15, 2023 at 4:00pm
(PDT) / August 16, 2023 at 9:00am (AEST).
The webinar will cover highlights from AVITA
Medical’s recent second quarter 2023 webcast with commercial
revenue up 42% compared to the same period in 2022, business
highlights, revenue guidance, and conclude with Q&A.
To register for the presentation, please follow
this Zoom link:
https://us02web.zoom.us/webinar/register/WN_QYXQA5P-TsGjPVD01tULxw
Participants are invited to submit questions via
the registration page or during the webinar via the chat function.
A replay will be available on the AVITA Medical website,
ir.avitamedical.com, following the presentation.
ABOUT AVITA MEDICAL, INC.AVITA
Medical® is a regenerative medicine company leading the development
and commercialization of devices and autologous cellular therapies
for skin restoration. The RECELL® System technology platform,
approved by the FDA for the treatment of thermal burn wounds and
full-thickness skin defects and for repigmentation of stable
depigmented vitiligo lesions, harnesses the regenerative properties
of a patient’s own skin to create Spray-On Skin™ cells. Delivered
at the point-of-care, RECELL enables improved clinical outcomes.
RECELL is the catalyst of a new treatment paradigm and AVITA
Medical is leveraging its proven and differentiated capabilities to
develop first-in-class cellular therapies for multiple
indications.
In international markets, AVITA Medical products
are approved under the RECELL System brand to promote skin healing
in a wide range of applications including burns, soft tissue
repair, vitiligo, and aesthetics. The RECELL System is
TGA-registered in Australia, received CE-mark approval in Europe
and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
FORWARD-LOOKING STATEMENTS This
press release includes forward-looking statements. These
forward-looking statements generally can be identified by the use
of words such as “anticipate,” “expect,” “intend,” “could,” “may,”
“will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,”
“target,” “project,” “continue,” “outlook,” “guidance,” “future,”
other words of similar meaning and the use of future dates.
Forward-looking statements in this press release include, but are
not limited to, statements concerning, among other things, our
ongoing clinical trials and product development activities,
regulatory approval of our products, the potential for future
growth in our business, and our ability to achieve our key
strategic, operational, and financial goal. Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Each forward-looking statement contained in
this press release is subject to risks and uncertainties that could
cause actual results to differ materially from those expressed or
implied by such statements. Applicable risks and uncertainties
include, among others, the timing and realization of regulatory
approvals of our products; physician acceptance, endorsement, and
use of our products; failure to achieve the anticipated benefits
from approval of our products; the effect of regulatory actions;
product liability claims; risks associated with international
operations and expansion; and other business effects, including the
effects of industry, economic or political conditions outside of
the company’s control. Investors should not place considerable
reliance on the forward-looking statements contained in this press
release. Investors are encouraged to read our publicly available
filings for a discussion of these and other risks and
uncertainties. The forward-looking statements in this press release
speak only as of the date of this release, and we undertake no
obligation to update or revise any of these statements.
FOR FURTHER INFORMATION:
Investors & MediaAVITA Medical,
Inc.Jessica EkebergPhone +1-661-904-9269
investor@avitamedical.commedia@avitamedical.com |
Avita Medical (NASDAQ:RCEL)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Avita Medical (NASDAQ:RCEL)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024